Chris Packard, University of Glasgow, UK, discusses whether mediation by EPA, EPA containing lipids, or metabolic products of EPA can help explain the disproportionate reduction in ASCVD risk compared to TG lowering in the REDUCE-IT trial.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
